Scalper1 News
While the approval of AbbVie’s (ABBV) hepatitis C regimen Viekira Pak hogged most of the headlines, over the past week the FDA has approved a whole passel of medicines that could be blockbusters for their makers. Here’s a short list of some of the most significant: Bristol-Myers (BMY) won approval for Opdivo for melanoma on Monday, which was something of a surprise since the FDA’s deadline was in March. Opdivo is a PD-1 inhibitor, a hot new class Scalper1 News
Scalper1 News